Apyx Medical Corp

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apyx Medical Corp reports Q4 revenue decline, eyes 2023 growth

Apyx Medical Corp faced revenue challenges in Q4 2022, but secured new clearances and credit facilities.
The company anticipates improved revenue and profitability in 2023 with strategic initiatives.
Despite losses and reduced cash reserves, Apyx aims to enhance product offerings and financial stability.
Management's actions aim to address concerns and position the company for growth in 2023.

Apyx Medical Corp reports Q1 revenue beat but faces cost challenges

Apyx Medical Corp faced mixed results in Q1 2023 with revenue exceeding expectations but a decline in gross profit and net loss.
The company showcased strengths in OEM sales, product launches, and property transactions, while grappling with challenges in certain sales segments.
With revised revenue guidance, margin expectations, and growth opportunities, Apyx has a strategic roadmap for future performance improvements.

Apyx Medical Corp reports strong Q2 growth and reaffirms 2023 guidance

Apyx Medical Corp demonstrated robust growth in Q2 2023, driven by Advanced Energy product sales and operational efficiency improvements.
While facing challenges in certain regions and managing operating expenses, the company's strategic initiatives and revenue diversification are key strengths.
With reaffirmed financial guidance and opportunities for market expansion, Apyx is poised for continued growth and innovation in the medical device industry.

Apyx Medical Corp reports robust Q3 performance and strategic initiatives

Apyx Medical Corp's Q3 2023 earnings call showcased strong revenue growth, improved gross profit margins, and strategic initiatives to address challenges. With a focus on operational efficiency and new product introductions, the company aims to drive future growth and profitability.

Apyx Medical Corp reports strong Q4 revenue growth and eyes market expansion

Apyx Medical Corp delivered strong revenue growth in Q4 2023 driven by Advanced Energy products and international sales performance.
While facing challenges in net loss and operating expenses, the company's technology and clinical support remain key strengths.
Opportunities lie in financial growth targets, market recognition, and leveraging positive feedback to drive future success.
Overall, Apyx Medical Corp's performance reflects resilience and potential for growth in the medical technology sector.

Apyx Medical Corp reports Q1 revenue decline, focuses on cost control

Apyx Medical Corp faced revenue decline in Q1 2024, driven by lower Advanced Energy sales.
The company showcased strengths in cost control, operational achievements, and revenue diversification.
Challenges include declining Advanced Energy sales and a projected net loss for 2024.
Opportunities lie in driving Renuvion technology adoption and addressing segment sales challenges.

Apyx Medical Corp reports Q3 revenue decline, bets on Ayon

Apyx Medical Corp's Q3 2024 performance reflects a mixed financial picture with revenue decline but promising growth in key segments like disposable handpieces.
Management's strategic initiatives, including the Ayon system launch and cost-saving measures, aim to drive future growth and achieve cash flow breakeven by 2027.
While facing revenue challenges and financial losses, the company's focus on operational efficiency and product innovation presents opportunities for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices, and supplier and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the publication of a peer-reviewed article in the journal, Lasers in Surgery and Medicine, the official journal of the American Society for Laser Medicine & Surgery, featuring the results of

Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion® Dermal Handpiece Using Apyx's Helium Plasma Technology for Dermal Resurfacing Procedures

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2021 will be released before the market opens on Thursday, March 17th. Management will host a conference call at 8:00 a.m. Eastern Tim

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2021. Preliminary Fourth Quarter 2021 Revenue Summary: Total revenue in a range of $16.3 to $16.8 million, repres

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results

Apyx Medical Corp (APYX) CEO Charles Goodwin on Q3 2021 Results - Earnings Call Transcript

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its third quarter ended September 30, 2021 and updated its financial outlook for the full year ending December 31, 2021. Third Quarter 2021 Financial Summary: Total revenue of

Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences: The 12th Annual Craig-Hallum Alpha Select Conference Management will participate in virtual 1x1 meetings on Tuesday

Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November and December

Apyx (APYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Apyx Medical (APYX) Q3 Earnings Expected to Decline

Fennec Pharmaceuticals

Safe Bulkers

VirTra

SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.

4 Breakout Stocks for Impressive Returns

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the third quarter of fiscal year 2021 will be released after the market closes on Thursday, November 11th. Management will host a conference call at 5:00 p.m. Eastern Ti

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2021 Financial Results on November 11, 2021

Apyx (APYX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Apyx (APYX) Moves 10.9% Higher: Will This Strength Last?

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the Colliers Securities 2021 Institutional Investor Conference, which is being held virtually on Thursday, September 9th. Management will participate in 1x1 mee

Apyx Medical Corporation to Participate in the Colliers Securities 2021 Institutional Investor Conference

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. Ms. Levine will serve as a Director and member of the Regulatory Compliance Committee. “I am pleas

Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company's Board of Directors

The shares of Apyx Medical Corp (NASDAQ: APYX) increased by over 19% during intraday trading. This is why it happened.

Apyx Medical Shares Increases Over 19% Intraday: Why It Happened

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2021 Results - Earnings Call Transcript

Apyx (APYX) delivered earnings and revenue surprises of 14.29% and 25.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Apyx Medical (APYX) Reports Q2 Loss, Tops Revenue Estimates

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2021 and updated its financial outlook for the full year ending December 31, 2021. Second Quarter 2021 Financial Summary: Total revenue of $1

Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook

Will Apyx Medical (APYX) Report Negative Earnings Next Week? What You Should Know

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the second quarter of fiscal year 2021 will be released before the market opens on Thursday, August 12th. Management will host a conference call at 8:00 a.m. Eastern Tim

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2021 Financial Results on August 12, 2021

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the JMP Securities Life Sciences Conference, which is being held virtually from June 16th-17th. Management will participate in a fireside chat on Wednesday, Jun

Apyx Medical Corporation to Participate in the JMP Securities Life Sciences Conference

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”), which is intended to obtain a specific clinical indication for the use of Renuvion in dermal resu

Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of Renuvion® in Dermal Resurfacing Procedures

Apyx Medical Corporation's (APYX) CEO Charlie Goodwin on Q1 2021 Results - Earnings Call Transcript

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its first quarter ended March 31, 2021, and updated financial expectations for the full year ending December 31, 2021. First Quarter 2021 Financial Summary: Total revenue of $

Apyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook

Analysts Estimate Apyx Medical (APYX) to Report a Decline in Earnings: What to Look Out for

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2021 will be released before the market opens on Wednesday, May 12. Management will host a conference call at 8:00 a.m. Eastern Time on

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q4 2020 Results - Earnings Call Transcript

News for Apyx Medical Corp Stock (APYX)